Researchers at the University of Zurich and Balgrist University Hospital have achieved promising results in treatment with the antibody NG 101 (anti-Nogo-A): In a clinical study with 126 participants, 78 of whom were injected with the antibody, patients with acute incomplete spinal cord injury achieved significant improvements - both in the conscious control of the paralysed muscles and in their independence in everyday life. Patients with complete paraplegia did not benefit from the treatment.
How does it work? The antibody NG 101 blocks an endogenous protein that hinders the regeneration of damaged nerve fibres. The aim of the treatment is to reduce the body's own inhibitory mechanisms and thus promote the regeneration of the spinal cord.
Further studies are needed to confirm the success of antibody therapy for incomplete paraplegia. Click here for the article on watson.ch (in German) and here for the study in the journal ‘The Lancet Neurology’.
A patient from the Clinic for Paraplegiology - Spinal Cord Injury Centre at Heidelberg University Hospital with Laura Heuterhaus, Study Nurse, during the clinical trial. Picture: © Heidelberg University Hospital
Marketplace
NG 101 antibody: new hope for spinal cord injuries
Researchers at the University of Zurich and Balgrist University Hospital have achieved promising results in treatment with the antibody NG 101 (anti-Nogo-A): In a clinical study with 126 participants, 78 of whom were injected with the antibody, patients with acute incomplete spinal cord injury achieved significant improvements - both in the conscious control of the paralysed muscles and in their independence in everyday life. Patients with complete paraplegia did not benefit from the treatment.
How does it work? The antibody NG 101 blocks an endogenous protein that hinders the regeneration of damaged nerve fibres. The aim of the treatment is to reduce the body's own inhibitory mechanisms and thus promote the regeneration of the spinal cord.
Further studies are needed to confirm the success of antibody therapy for incomplete paraplegia. Click here for the article on watson.ch (in German) and here for the study in the journal ‘The Lancet Neurology’.
A patient from the Clinic for Paraplegiology - Spinal Cord Injury Centre at Heidelberg University Hospital with Laura Heuterhaus, Study Nurse, during the clinical trial. Picture: © Heidelberg University Hospital